Alterity Therapeutics Limited (ATHE)
NASDAQ: ATHE · IEX Real-Time Price · USD
2.070
+0.050 (2.48%)
At close: Mar 28, 2024, 3:59 PM
2.060
-0.010 (-0.48%)
After-hours: Mar 28, 2024, 4:12 PM EDT
Alterity Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for ATHE stock have an average target of 7.00, with a low estimate of 4.00 and a high estimate of 10. The average target predicts an increase of 238.16% from the current stock price of 2.07.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ATHE stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
Total | 1 | 1 | 1 | 1 | 2 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Benchmark | Benchmark | Buy Reiterates $4 | Buy | Reiterates | $4 | +93.24% | Mar 7, 2024 |
Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Maintains $20 → $10 | Strong Buy | Maintains | $20 → $10 | +383.09% | Jun 5, 2023 |
Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | +866.18% | Aug 3, 2022 |
Benchmark | Benchmark | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Aug 20, 2021 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
n/a
EPS Next Year
n/a
No financial forecasts available for this stock
Revenue Forecast
No data available
Revenue Growth
No data available
EPS Forecast
No data available
EPS Growth
No data available
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.